Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm

Interventions

BIOLOGICAL: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
BIOLOGICAL: Recombinant Interferon Alfa-2b
BIOLOGICAL: Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
BIOLOGICAL: Sargramostim

Sponsor

National Cancer Institute (NCI)